# US 2010/0166731 A1 · Methods and Compositions for Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166731 A1
- Document ID: US20100166731A1
- Status: Published application
- Kind: A1
- Application number: 11/992,798
- Filed: 2006-09-29
- Published: 2010-07-01
- Earliest claimed: 2005-09-30
- Inventors: Steven R. Bartz; Peter Linsley
- Web page: https://patentgrep.com/patent/US20100166731A1

## CPC

- C12Q 1/485: {involving kinase}
- A61P 35/04: specific for metastasis
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/11: Antisense
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/15: Nucleic acids forming more than 2 strands, e.g. TFOs
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods and compositions for treating cancers by reducing the expression or activity of one or more of the genes encoding protein kinases ATR, MAST2, MAP3K6, TBK1, ADRBK2, CDKL2, LATS2, STK32B, STK11, DDR13 PSKH2, and NEK8, and/or the encoded kinases. The invention also relates to methods and compositions for determining the responsiveness of a cancer patient to anti-cancer drugs based on the status of one or more of such kinases. The invention further relates to methods and compositions for screening compounds that can be used to modulate the expression/activity of these kinases.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for treating a mammal having a cancer, comprising
(a) administering to said mammal a therapeutically effective amount of a first agent, said first agent reducing the expression of a gene encoding a protein kinase selected from the group consisting of ATR, MAST2, MAP3K6, TBK1, ADRBK2, CDKL2, LATS2, STK32B, STK11, DDR1, PSKH2, and NEK8 and/or activity of said protein kinase; and
(b) administering to said mammal a therapeutically effective amount of a composition comprising one or more anti-cancer agents.

### Claim 3 (depends on 2)

The method of claim 2, wherein said first agent comprises a substance selected from the group consisting of siRNA, antisense nucleic acid, ribozyme, and triple helix forming nucleic acid, each being capable of reducing the expression of said gene in cells of said cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein said first agent comprises an siRNA targeting said gene.

### Claim 5 (depends on 4)

The method of claim 4, wherein said first agent comprises 2, 3, 4, 5, 6, or 10 different siRNAs targeting said gene.

### Claim 6 (depends on 2)

The method of claim 2, wherein said first agent comprises a substance selected from the group consisting of antibody, peptide, and small molecule, each being capable of reducing the activity of said protein kinase in cells of said cancer.

### Claim 7 (depends on 2)

The method of claim 2, wherein said one or more anti-cancer agents are selected from the group consisting of topoisomerase I inhibitor, topoisomerase II inhibitor, DNA binding agent, anti-metabolite, anti-mitotic agent, and ionizing radiation.

### Claim 8 (depends on 7)

The method of claim 7, wherein said one or more anti-cancer agents are selected from the group consisting of camptothecin, cisplatin, gemcitabine, hydoxyurea, bleomycin, L-001000962-000Y, and 5-fluorouracil.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

A method for evaluating sensitivity of a cell to the growth inhibitory effect of an anti-cancer agent, said method comprising determining a level of activity of a protein kinase selected from the group consisting of ATR, MAST2, MAP3K6, TBK1, ADRBK2, CDKL2, LATS2, STK32B, STK11, DDR1, PSKH2, and NEK8, and determining whether said level of activity is below a predetermined threshold level, wherein said activity level below the predetermined threshold level indicates that said cell is sensitive to the growth inhibitory effect of said anti-cancer agent.

### Claim 19 (depends on 18)

The method of claim 18, wherein said anti-cancer agent is selected from the group consisting of topoisomerase I inhibitor, topoisomerase II inhibitor, DNA binding agent, anti-metabolite, anti-mitotic agent, and ionizing radiation.

### Claim 20 (depends on 19)

The method of claim 19, wherein said anti-cancer agent is selected from the group consisting of camptothecin, cisplatin, gemcitabine, hydoxyurea, bleomycin, L-001000962-000Y, and 5-fluorouracil.

### Claim 21 (depends on 18)

The method of claim 18, wherein said cell is a human cell.

### Claim 22

A method for enhancing sensitivity of a cell to an anti-cancer agent, comprising contacting said cell with an agent that reduces the expression of a gene encoding a protein kinase selected from the group consisting of ATR, MAST2, MAP3K6, TBK1, ADRBK2, CDKL2, LATS2, STK32B, STK11, DDR1, PSKH2, and NEK8 and/or the activity of said protein kinase, said agent being in an amount sufficient to enhance sensitivity of said cell to an anti-cancer agent.

### Claim 23 (depends on 22)

The method of claim 22, wherein said agent comprises a substance selected from the group consisting of siRNA, antisense nucleic acid, ribozyme, and triple helix forming nucleic acid.

### Claim 24 (depends on 22)

The method of claim 22, wherein said agent comprises a substance selected from the group consisting of antibody, peptide, and small molecule.

### Claim 25 (depends on 23)

The method of claim 23, wherein said anti-cancer agent is selected from the group consisting of topoisomerase I inhibitor, topoisomerase II inhibitor, DNA binding agent, anti-metabolite, anti-mitotic agent, and ionizing radiation.

### Claim 26 (depends on 23)

The method of claim 23, wherein said anti-cancer agent is selected from the group consisting of camptothecin, cisplatin, gemcitabine, hydoxyurea, bleomycin, L-001000962-000Y, and 5-fluorouracil.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

A method of identifying a substance that is capable of enhancing sensitivity of a cell of a cell type to the growth inhibitory effect of an anti-cancer agent, wherein said substance is capable of reducing the expression of a first gene encoding a protein kinase selected from the group consisting of ATR, MAST2, MAP3K6, TBK1, ADRBK2, CDKL2, LATS2, STK32B, STK11, DDR1, PSKH2, and NEK8 and/or the activity of said protein kinase, said method comprising:
(a) contacting a first cell of said cell type expressing said first gene with said anti-cancer agent in the presence of said candidate substance and measuring a first growth inhibitory effect;
(b) contacting a second cell of said cell type expressing said first gene with said anti-cancer agent under the same conditions as (a) except in the absence of said candidate substance and measuring a second growth inhibitory effect; and
(c) comparing said first and second growth inhibitory effects measured in said step (a) and (b),
wherein a greater first growth inhibitory effect than said second growth inhibitory effect identifies said candidate substance as capable of enhancing sensitivity of a cell to the growth inhibitory effect of said anti-cancer agent.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 40)

The method of claim 40, wherein said substance comprises a molecule that reduces expression of said gene.

### Claim 44 (depends on 43)

The method of claim 43, wherein said substance comprises an siRNA targeting said gene.

### Claim 45 (depends on 44)

The method of claim 44, wherein said substance comprises 2, 3, 4, 5, 6, or 10 different siRNAs targeting said gene.

### Claim 46 (depends on 45)

The method of claim 45, wherein the total siRNA concentration of said different siRNAs in said substance is an optimal concentration for silencing said gene, wherein said optimal concentration is a concentration further increase of which does not increase the level of silencing substantially.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53 (depends on 40)

The method of claim 40, wherein said anti-cancer agent is selected from the group consisting of a topoisomerase I inhibitor, a topoisomerase II inhibitor, a DNA binding agent, anti-metabolite, anti-mitotic agent, and ionizing radiation.

### Claim 54 (depends on 53)

The method of claim 53, wherein said anti-cancer agent is selected from the group consisting of camptothecin, cisplatin, gemcitabine, hydoxyurea, bleomycin, L-001000962-000Y, and 5-fluorouracil.

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)
